Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.

Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W.

Addict Biol. 2009 Jul;14(3):328-37. doi: 10.1111/j.1369-1600.2009.00159.x.

PMID:
19523047
2.

The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.

Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W.

Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66. Epub 2007 Mar 26.

PMID:
17379484
3.

Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?

Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, Weltman M, Haber P.

Addiction. 2008 Jun;103(6):953-9. doi: 10.1111/j.1360-0443.2008.02215.x.

PMID:
18482418
4.

Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.

Rösner S, Leucht S, Lehert P, Soyka M.

J Psychopharmacol. 2008 Jan;22(1):11-23. doi: 10.1177/0269881107078308.

PMID:
18187529
5.

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.

Rubio G, Jiménez-Arriero MA, Ponce G, Palomo T.

Alcohol Alcohol. 2001 Sep-Oct;36(5):419-25. Erratum in: Alcohol Alcohol 2002 Jan-Feb;37(1):105.

PMID:
11524308
6.

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.

Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS.

Addiction. 2006 Oct;101(10):1451-62.

PMID:
16968347
7.
8.
9.

New pharmacotherapies for alcohol dependence.

Graham R, Wodak AD, Whelan G.

Med J Aust. 2002 Jul 15;177(2):103-7. Review.

PMID:
12098353
10.

Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.

Kranzler HR, Van Kirk J.

Alcohol Clin Exp Res. 2001 Sep;25(9):1335-41.

PMID:
11584154
11.

Rationale for combining acamprosate and naltrexone for treating alcohol dependence.

Mason BJ.

J Stud Alcohol Suppl. 2005 Jul;(15):148-56; discussion 140. Review.

PMID:
16223066
12.

The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.

Snyder JL, Bowers TG.

Am J Drug Alcohol Abuse. 2008;34(4):449-61. doi: 10.1080/00952990802082198.

PMID:
18584575
13.

Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.

Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A; PREDICT Study Research Team.

Alcohol Clin Exp Res. 2009 Apr;33(4):674-83. doi: 10.1111/j.1530-0277.2008.00884.x. Epub 2009 Jan 20.

PMID:
19170666
14.

Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.

Soyka M, Rösner S.

Curr Drug Abuse Rev. 2008 Nov;1(3):280-91. Review.

PMID:
19630726
15.

[The pharmacologic treatment of the alcohol dependence].

Castro LA, Baltieri DA.

Rev Bras Psiquiatr. 2004 May;26 Suppl 1:S43-6. Epub 2005 Jan 4. Portuguese.

16.

Pharmacologic approaches to the management of alcoholism.

Anton RF.

J Clin Psychiatry. 2001;62 Suppl 20:11-7. Review.

17.

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.

Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM.

Pharmacogenet Genomics. 2011 Dec;21(12):902-5. doi: 10.1097/FPC.0b013e32834c5445.

PMID:
21946895
18.

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Bouza C, Angeles M, Muñoz A, Amate JM.

Addiction. 2004 Jul;99(7):811-28. Review. Erratum in: Addiction. 2005 Apr;100(4):573. Magro, Angeles [corrected to Angeles, Magro].

PMID:
15200577
19.

Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.

Mann K, Vollstädt-Klein S, Reinhard I, Leménager T, Fauth-Bühler M, Hermann D, Hoffmann S, Zimmermann US, Kiefer F, Heinz A, Smolka MN.

Alcohol Clin Exp Res. 2014 Nov;38(11):2754-62. doi: 10.1111/acer.12546.

PMID:
25421512
20.

Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.

Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K.

Eur Addict Res. 2005;11(2):83-91.

PMID:
15785069

Supplemental Content

Support Center